Chloroquine retinopathy
Chloroquine was first introduced into clinical practice, as an antimalarial, in the early 1940s, as part of an extensive American programme to synthesize safer alternatives to quinacrine. Its introduction constituted a great advance in the fight against malaria and, subsequently, its anti-inflammatory actions were found to be useful in the treatment of rheumatoid arthritis and other connective tissue diseases. However, in 1957 the first reports of ocular toxicity began to appear. Subsequently, chloroquine retinopathy has been most carefully studied in patients with rheumatoid arthritis, with less attention directed to retinopathy in the context of malaria prophylaxis and treatment.
The first noticeable effect of chloroquine on the eye is the formation of corneal micro-deposits, affecting 95% of patients taking chloroquine at a dose of 250 mg daily'. Usually these are asymptomatic, although a few patients complain of halos around bright lights, and they resolve once the drug is stopped. Later, reversible impairment of ciliary accommodation may develop and there are unproven suggestions that chloroquine may induce cataracts2. Certainly, lens opacities, in the form of tiny white flecks behind the posterior lens capsule, are seen in up to 40% of patients receiving c h l~r o q u i n e~~~.
In the retina, chloroquine deposition takes place in the retinal pigment epithelium (RPE). Initially there is vascular dilatation in the choroid and swelling of the RPE. Cells of the RPE then enlarge, separate from the basement membrane, and migrate upwards into the nerve fibre layer causing oedema. The intracellular pigment becomes granular and the pigmented cells aggregate, leading to the stippling seen on fundoscopy. In classical chloroquine retinopathy there is stippled hyper-pigmentation of the macula surrounded by a halo of de-pigmentation then a further concentric ring of increased pigmentation, thus producing the 'bull's eye' pattern. These macular changes are accompanied by the development of scotomata and, if left unchecked, lead to permanent loss of central vision. Subsequently, thickening and sclerosis of the choroidal vessels develops with segmental constriction leading to retinal vascular insufficiency. The peripheral retina becomes finely granular with a prominent choroidal pattern, the optic disc becomes pale and there is a corresponding loss of peripheral vision2. Eventually the patient is left blind.
The mechanism by which chloroquine induces retinal damage is not fully understood and is probably multifactorial. The histological changes, as detailed above, have been clearly documented5. In addition, there appear to be a number of ultra-structural and functional effects of the drug. Chloroquine produces membrane inclusions in ganglion cells, retinal neurones and RPE cells. It may be that the inclusions in the cells of the RPE impair their metabolism and hence retinal nutrition, as the photoreceptors are entirely dependent on the RPE for their nutrition. Photoreceptor cells are highly metabolically active and continually replace their outer segment (ROS), a process involving the production of rhodopsin. Chloroquine interferes with rhodopsin synthesis acutely and has been shown to induce ultrastructural changes in the ROS6, associated with shortening and damage, and to a reduction in the number of photo receptor^^. Evidence also suggests that chloroquine impairs the RPE cells' immunophagocytic role, by causing a reversible malfunction of phagolysosomes, thus leading to inefficient clearing of photoreceptor debrisXs9. Chloroquine binds to DNA, particularly within mitochondrialO. This may explain why cardiac muscle is more susceptible than striated muscle, giving rise to cardiomyopathies in a number of African patients who had self-medicated with large cumulative doses of chloroquine11,'2. Its relevance to retinopathy is unknown.
There has been much discussion as to safe levels of chloroquine ingestion and whether it is the daily dose or the total cumulative dose which governs toxicity. The evidence seems to suggest that the daily dose is more important with a maximum recommended dose of 4 mg/ kg/dayI3 of chloroquine phosphate, equivalent to 2.5 mg/ kg/day of chloroquine base. Usually this is taken to imply a dose of 250 mg chloro-quine phosphate per day14. In rheumatological practice, most authorities accept that the risk of chloroquine retinopathy is very small provided a dose of 250 mg/day chloroquine phosphate is not ex~eeded'~,'~, although Bernstein found that 1 1 ' YO of patients with chloroquine retinopathy had apparently developed this at doses of 250 mg/dayi6. Making comparisons between different studies is hampered by a lack of agreement as to what constitutes retinopathy. Definite retinopathy should be diagnosed when there is permanent functional impairment, e.g. scotomata and/or reduction in acuity. Due to uneven distribution, toxicity can occur if the dose is calculated using the weight of an overweight patient. Doses must therefore be titrated to the lean body weight15.
Although retinopathy can occur once the cumulative dose exceeds 100 g, the risk does not significantly increase until it exceeds 300 g, and a 50% increase in risk has been demonstrated at doses in excess of 900 g17. Mackenzie argues that the relationship between cumulative dose and retinopathy is only seen with high daily doses and disappears if the daily dose is not exce~sive'~.
Certainly, in 929 patients taking < 250 mg/day none developed retinopathy despite some ingesting > 1000 g of chloroquinel8. A recent study of 588 missionaries, reflecting 6250 person years of chloroquine use, included 53 who had ingested > 300 g. Only one person developed retinopathy and she had been taking daily doses of 250-500 mg chloroquine for fibromyo~itis'~. Although seemingly encouraging, it is worrying that the ophthalmological assessments were not carried out by ophthalmologists and that perimetry was not assessed. Thus early changes in macular pigmentation and scotomata may have been missed with subsequent under-reporting of early retinopathy.
The paper by Waddell in this issue illustrates (p. 10) 21 Ugandan patients with chloroquine retinopathy who, on average, took two courses of chloroquine each month. Depending on which salt they took, this equates to a daily intake of 16C200 mg/day, well below the maximum level considered 'safe'. Similarly Ihenacho12 describes 11 Nigerians with retinopathy, most of whom had taken equivalent daily doses of 133-21 3 mg/day and Stilma found, in just 1 month's observations, severe retinopathy in Ghanaian patients ingesting as little as 50 g cumulatively20. Whilst these results may simply represent bias in small samples it does raise the question as to whether Africans are more sensitive to the retinotoxic effects of chloroquine.
It is known that the iris and choroid of pigmented animals take up and store chloroquine in higher concentrations than other tissues, and that the concentration of chloroquine is much lower in the tissues of albino animals21.22. Chloroquine binds avidly to melanin and appears to reduce melanin's ability to absorb light23. This may result in increased local concentrations of both free radicals and photochemical toxic products, damaging the photoreceptor cells directly and also impairing the ability of the RPE to supply them. The higher light intensities encountered in Africa would intensify these effects and there is evidence from animal models that light exacerbates chloroquine retinopathy whilst keeping the animals in the dark greatly reduces it24. Light also stimulates the shedding of old photoreceptor ROSS which would potentiate the effects of an RPE failing in its immunophagocytic role. In Africans the increased melanin in the RPE may result in higher concentrations of chloroquine and thus contribute to an increased risk of retinal damage. Melanin can bind up to 3% of its own weight in c h l o r o q~i n e~~. In someone with black skin this would represent a significant 'depot' storage of chloroquine which would slowly leach back into the circulation. This, however, cannot be the complete explanation as chloroquine retinopathy has been induced in albino animals5.
At least 30% of ingested chloroquine is metabolized in the liver by de-ethylation and 60% excreted through the kidneys. The renal and hepatic function of the Ugandan and Nigerian patients described is unknown, but in areas with high levels of endemic chronic hepatitis, impairment of hepatic metabolism may be important. There are, therefore, several mechanisms by which a black African may be more at risk of chloroquine retinopathy.
Unfortunately, patients in Africa frequently present with late retinopathy which may progress despite discontinuation of treatment. If we are to avoid this situation, it is important to be vigilant to the early signs. Patients usually complain of difficulty reading with words or letters missing, blurred distance vision, missing or blacked out areas, light flashes and photophobia. Most patients with definite retinal changes are symptomatic though a few may not be2. The earliest changes, macular spickled pigmentation, can be difficult to discern given the wide variation in normal appearance and the similarities with age-regulated change. The appearance of a scotomata to a 3 mm red test object has been recommended as the most reliable indicator of impending retinal toxicity26 but 6% of the normal population have this defect, limiting its usefulness unless patients are screened before commencing chloroquine. Another indicator is a 5" visual field constriction but this again requires a baseline observation2. Some authorities recommend the Amsler Grid as a simple, inexpensive and efficient way of assessing visual fields as screening for early retinopathy'. Tests of colour vision, particularly the most commonly available Ishihara tests, are unhelpful'. There is, thus, no entirely reliable method of detecting early chloroquine retinopathy and therefore regular screening with both fundoscopy and visual field testing of patients at risk is recommended.
As described in Waddell's paper, many African patients are taking chloroquine unnecessarily and developing retinopathy. Further studies are needed to ascertain whether there are racial differences in the susceptibility to chloroquine retinopathy. Meanwhile, the public in malarious areas must be educated as to the potentially blinding consequences of chloroquine overuse whilst at the same time not increasing morbidity and mortality from malaria by delaying treatment.
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The Barker Memorial Prize
In August 1994 Drs Anthony and Maggie Barker died on their beloved tandem when they were in collision with a lorry while cycling in the Lake District to celebrate their golden wedding, inseparable in death as in life. They had spent their lives promoting health and wholeness, caring passionately for people and sharing all that they possessed. Deeply influenced by the Zulu people among whom they worked for 30 years, Anthony often quoted the Zulu saying 'Umunthu ungumunthu ngaBanthu' (a person is a person because of people). Indeed, they inspired thousands of doctors, medical students, nurses, patients, friends, and even politicians, not only in South Africa but worldwide. Arriving at Nqutu in Zululand ourselves in 1969 as young doctors with small children, my husband and I were met before dawn by Anthony, exuberantly driving the hospital's ancient Land Rover-he never owned a car himself. That first day was typical of many. After a chapel service there were ward rounds, teaching hospital style, interrupted by a communal breakfast in their tiny portion of the staff house. Then there was an autopsy to be done on a decomposing body beside the river. They both took turns in Outpatients (more a casualty department than a clinic) and each day there was a district 'clinic' to visit, where a hundred or so patients queued outside a storekeeper's back room.
Caesarean sections were done under local anaesthetic, with a remarkably low perinatal mortality, but Anthony, who had his FRCS as well as his MD, was a fine surgeon and quite capable of complex intraabdominal operations. Somehow there was time to lecture to the nurses and to mastermind the hospital administration, and on our first day, as on most, Anthony revelled in the communal evening softball game while Maggie did incredible things with her sewing needle. After supper there was home-brew and music. One was enthralled by their utter commitment and integrity.
In his excellent biography Anthony and Maggie Barker: Lives in Tandem, Barry Adams, past professor of medicine at the University of Natal, quotes extensively from Anthony's own writings. He was a fine writer, as well as an orator, of great style and precision as well as candour, humour and humility.
Anthony's second career was as a consultant in Accident and Emergency at St. George's Hospital in London, ably assisted by Maggie as his part-time SHO. His all embracing skills and gift for teaching in the clinical situation bought swift recognition and he became Vice Dean of the medical school. After retirement they worked at the Alexandra Clinic in a poor,violent and overcrowded township near Johannesburg. Returning again to London they poured their energies into voluntary work and environmental causes. Anthony also became Assistant Editor of Tropical Doctor. A special issue of this journal devoted to
